amitriptyline has been researched along with ENT Diseases in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pech, A | 1 |
| Cahier, S | 1 |
1 trial available for amitriptyline and ENT Diseases
| Article | Year |
|---|---|
[Combination of 2 products with antidepressive and tranquillizing actions. Their interest in an ORL and facial surgery department].
Topics: Adult; Aged; Amitriptyline; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Face; Huma | 1974 |